• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

BMC Infect Dis . Prognostic significance of chronic kidney disease and impaired renal function in Japanese patients with COVID-19

tetano

Editor, Senior Moderator
BMC Infect Dis


. 2024 May 25;24(1):527.
doi: 10.1186/s12879-024-09414-w. Prognostic significance of chronic kidney disease and impaired renal function in Japanese patients with COVID-19

Hiromu Tanaka[SUP] 1 [/SUP], Shotaro Chubachi[SUP] #[/SUP][SUP] 2 [/SUP], Takanori Asakura[SUP] #[/SUP][SUP] 3 4 5 [/SUP], Ho Namkoong[SUP] 6 [/SUP], Shuhei Azekawa[SUP] 1 [/SUP], Shiro Otake[SUP] 1 [/SUP], Kensuke Nakagawara[SUP] 1 [/SUP], Takahiro Fukushima[SUP] 1 [/SUP], Ho Lee[SUP] 1 [/SUP], Mayuko Watase[SUP] 1 [/SUP], Kaori Sakurai[SUP] 1 [/SUP], Tatsuya Kusumoto[SUP] 1 [/SUP], Katsunori Masaki[SUP] 1 [/SUP], Hirofumi Kamata[SUP] 1 [/SUP], Makoto Ishii[SUP] 1 7 [/SUP], Naoki Hasegawa[SUP] 6 [/SUP], Yukinori Okada[SUP] 8 9 10 [/SUP], Ryuji Koike[SUP] 11 [/SUP], Yuko Kitagawa[SUP] 12 [/SUP], Akinori Kimura[SUP] 13 [/SUP], Seiya Imoto[SUP] 14 [/SUP], Satoru Miyano[SUP] 15 [/SUP], Seishi Ogawa[SUP] 16 [/SUP], Takanori Kanai[SUP] 17 [/SUP], Koichi Fukunaga[SUP] 1 [/SUP]



Affiliations
Free article Abstract

Background: Renal impairment is a predictor of coronavirus disease (COVID-19) severity. No studies have compared COVID-19 outcomes in patients with chronic kidney disease (CKD) and patients with impaired renal function without a prior diagnosis of CKD. This study aimed to identify the impact of pre-existing impaired renal function without CKD on COVID-19 outcomes.
Methods: This retrospective study included 3,637 patients with COVID-19 classified into three groups by CKD history and estimated glomerular filtration rate (eGFR) on referral: Group 1 (n = 2,460), normal renal function without a CKD history; Group 2 (n = 905), impaired renal function without a CKD history; and Group 3 (n = 272), history of CKD. We compared the clinical characteristics of these groups and assessed the effect of CKD and impaired renal function on critical outcomes (requirement for respiratory support with high-flow oxygen devices, invasive mechanical ventilation, or extracorporeal membrane oxygen, and death during hospitalization) using multivariable logistic regression.
Results: The prevalence of comorbidities (hypertension, diabetes, and cardiovascular disease) and incidence of inflammatory responses (white blood counts, and C-reactive protein, procalcitonin, and D-dimer levels) and complications (bacterial infection and heart failure) were higher in Groups 2 and 3 than that in Group 1. The incidence of critical outcomes was 10.8%, 17.7%, and 26.8% in Groups 1, 2, and 3, respectively. The mortality rate and the rate of requiring IMV support was lowest in Group 1 and highest in Group 3. Compared with Group 1, the risk of critical outcomes was higher in Group 2 (adjusted odds ratio [aOR]: 1.32, 95% confidence interval [CI]: 1.03-1.70, P = 0.030) and Group 3 (aOR: 1.94, 95% CI: 1.36-2.78, P < 0.001). Additionally, the eGFR was significantly associated with critical outcomes in Groups 2 (odds ratio [OR]: 2.89, 95% CI: 1.64-4.98, P < 0.001) and 3 (OR: 1.87, 95% CI: 1.08-3.23, P = 0.025) only.
Conclusions: Clinicians should consider pre-existing CKD and impaired renal function at the time of COVID-19 diagnosis for the management of COVID-19.

Keywords: COVID-19; Estimated glomerular filtration rate; Japanese population; Renal insufficiency.

 
Back
Top Bottom